Clinical Trial

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Study acronym: e3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Protocol Amendment History 30 amendments
This ClinicalTrials.gov record has been amended 30 times since 2012-08-24; most recent amendment 2026-01-21.
Status change: Recruiting → Active, Not Recruiting 2019-06-20
Status change: Not Yet Recruiting → Recruiting 2014-01-30
Trial Details
NCT Number NCT01674140
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 1,939 participants
Start Date 2013-09-12
Primary Completion 2022-12-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-10